詳細(xì)介紹
孕激素受體(PR)
廣州健侖生物科技有限公司
人孕激素受體(PR)作為配體激活的轉(zhuǎn)錄因子,是類固醇激素受體家族的一員。PR有兩個(gè)異構(gòu)體PR-A(94kDa)和PR-B(114kDa)。雖然它們的轉(zhuǎn)錄活性相反,但它們的DNA和配體結(jié)合親和力相似。PR-B是孕激素敏感基因的激活劑,而PR-A則抑制PR-B功能。作為乳腺癌內(nèi)分泌治療參考依據(jù),PR與ER、HER-2已經(jīng)作為乳腺癌患者的研究檢測(cè)項(xiàng)目。
我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒:登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲(chóng)病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。
歡迎咨詢
歡迎咨詢
【產(chǎn)品介紹】
細(xì)胞定位:細(xì)胞核
克隆號(hào):Y85
同型:IgG
適用組織:石蠟/冰凍
陽(yáng)性對(duì)照:乳腺癌
抗原修復(fù):熱修復(fù)(EDTA)
抗體孵育時(shí)間:30-60min
產(chǎn)品編號(hào) | 抗體名稱 | 克隆型別 |
OB201 | PD-1(血管免疫母T細(xì)胞淋巴瘤標(biāo)記) | NAT105 |
OB202 | 兔抗人PDGFRα多克隆抗體 | polyclonal |
OB203 | PD-L1/CD274(細(xì)胞程序死亡配體1) | SP142 |
OB204 | Pgp(P-糖蛋白) | C494 |
OB205 | PGP9.5(蛋白基因產(chǎn)物9.5) | Polyclonal |
OB206 | PHH3(核心組蛋白3) | polyclonal |
OB207 | PLAP(胎盤堿性磷酸酶) | SP15 |
OB208 | PMS2(減數(shù)分裂后隔離加強(qiáng)子2) | EP51 |
OB209 | PR(孕激素受體) | Y85 |
OB210 | PR(孕激素受體) | 16 |
OB211 | Prolactin(催乳素) | polyclonal |
OB212 | Prostein (前列腺特異性蛋白) | 10E3 |
OB213 | PSA(前列腺特異性抗原) | EP-PR8 |
OB214 | PSAP(前列腺酸性磷酸酶) | PASE/4LJ |
OB215 | PSMA(前列腺膜特異抗原) | 3E6 |
OB216 | PTEN (10號(hào)染色體缺失磷酸酶及張力蛋白同源基因) | 6H2.1 |
想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼:
【公司名稱】 廣州健侖生物科技有限公司
【市場(chǎng)部】 歐
【】
【騰訊 】
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室
致力于再生細(xì)胞并培養(yǎng)新組織來(lái)治療衰竭性損傷和疾病(如帕金森病、心臟病和脊髓損傷)的研究人員,所面臨的一個(gè)主要挑戰(zhàn)是,創(chuàng)建一種簡(jiǎn)單、有效和無(wú)毒性的方法,來(lái)控制到特定細(xì)胞譜系的分化。Lee及其羅格斯大學(xué)、日本京都大學(xué)的同事們,發(fā)明了一種平臺(tái),他們稱之為NanoScript,對(duì)于基因表達(dá)領(lǐng)域的研究人員來(lái)說(shuō),這是一個(gè)重要的突破?;虮磉_(dá)是指細(xì)胞在生命過(guò)程中,把儲(chǔ)存在DNA順序中遺傳信息經(jīng)過(guò)轉(zhuǎn)錄和翻譯,轉(zhuǎn)變成具有生物活性的蛋白質(zhì)分子,對(duì)于通過(guò)干細(xì)胞治療的組織發(fā)育過(guò)程是很重要的。
干細(xì)胞具有很大的潛力應(yīng)用于各種醫(yī)學(xué)治療,因?yàn)樗鼈兡軌蚺囵B(yǎng)整個(gè)身體的組織。在許多組織中,干細(xì)胞作為一種內(nèi)部修復(fù)系統(tǒng),具有幾乎無(wú)限分裂和補(bǔ)充其他細(xì)胞的能力。
轉(zhuǎn)錄因子(TF)蛋白質(zhì)是基因表達(dá)的主要調(diào)控因子。TF蛋白在調(diào)控干細(xì)胞分化過(guò)程中發(fā)揮重要的作用。雖然有些人試圖制造行使天然轉(zhuǎn)錄因子功能的合成分子,但NanoScript是*個(gè)能夠與內(nèi)源DNA相互作用的納米材料TF蛋白質(zhì)。Lee關(guān)于NanoScript的這項(xiàng)研究,發(fā)表在zui近的美國(guó)化學(xué)學(xué)會(huì)期刊《ACS Nano》。該研究是由美國(guó)國(guó)立衛(wèi)生研究院(NIH)資助支持。
A major challenge for researchers working on regenerating cells and developing new tissue to treat failing lesions and diseases such as Parkinson's disease, heart disease, and spinal cord injury is creating a simple, effective, and non-toxic approach , To control the differentiation of specific cell lineages. Lee and his colleagues at Rutgers University and Kyoto University in Japan invented a platform that they call NanoScript, an important breakthrough for researchers in the field of gene expression. Gene expression refers to the cells in the life process, stored in the DNA sequence of genetic information through transcription and translation, into a biological activity of protein molecules, through the stem cell treatment of tissue development is very important.
Stem cells have great potential for use in a variety of medical treatments because they are capable of developing tissue throughout the body. In many tissues, stem cells act as an internal repair system that has the ability to divide and replenish other cells almost indefiniy.
Transcription factor (TF) proteins are the major regulatory elements of gene expression. TF protein plays an important role in the regulation of stem cell differentiation. Although some people try to make synthetic molecules that perform the function of natural transcription factors, NanoScript is the first TF protein of nanomaterials that interacts with endogenous DNA. Lee's research on NanoScript was published in the recent ACS Nano Journal. The study was funded by the National Institutes of Health (NIH).